

## PUBLICATION LIST - Prof. Dr. Edna Grünblatt

Researcher ORCID ID: [orcid.org/0000-0001-8505-7265](https://orcid.org/0000-0001-8505-7265)

No. of original works = 121; No. of original works (first/last author) = 33/33;

No. of other works = 56; No. Book & Book chapter = 12

Web of knowledge hirsch-index=41; Times cited= 6355

Scopus h-index=42; Citations=6630

ResearchGate RG score=49.31, h-index=48 (47 excluding self-citation); Citations=8580

Google Scholar h-index=51; i10-index=133; Citations=9939

### I. Original work (bioRxiv/ medRxiv)

1. Strom NI, Yu D, Gerring ZF....Walitza S,....**Grünblatt E**, Wagner M, Zwart JA, Breen G, Nestadt G, Metspalu A, Pario J, Arnold PD, Grice DE, Knowles JA, Ask H, Verweij KJH, Davis LK, Smit DJA, Crowley JJ, Mathews CA, Derks EM, Schard JM, Mattheisen M (2021) Genome-wide association study identifies new locus associated with OCD. MedRxiv. doi: <https://doi.org/10.1101/2021.10.13.21261078>
2. Yilmaz Z, Schaumberg K, Halvorsen M, Goodman EL, Brosof LC, Crowley JJ, AN Genetic Initiative, Eating Disorders PGC, TS/OCD PGC\*, et al (2020) Predicting eating disorder and anxiety symptoms using anorexia and obsessive-compulsive disorder polygenic scores. medRxiv. doi: <https://doi.org/10.1101/2020.07.02.20142844>. \* **Grünblatt E** member of OCD-PGC.
3. Bellenguez C, Küçükali F, Jansen I,..... **Grünblatt E**, ....Sims R, Van der Flier WM, Ruiz A, Ramirez A, Lambert JC (2020) Large meta-analysis of genome-wide association studies expands knowledge of the genetic etiology of Alzheimer's disease and highlights potential translational opportunities. medRxiv. doi: <https://doi.org/10.1101/2020.10.01.20200659>

### II. Original work peer-reviewed

1. Le Gruen Y, Belloy ME, Grenier-Boley B, de Rojas I, ....and the EADB group, the GR@ACE group, the DEGESCO group, the EADI group, the GERAD group, for the **EADB collaborators**, the GR@ACE collaborators, the DEGESCO collaborators, the DemGene collaborators, the GERAD collaborators. (2022) Rare APOE missense variant R251G is associated with reduced risk of Alzheimer's disease in APOE-ε4 carriers. Accepted. *JAMA Neurology*. \***Grünblatt E** contribution with VITA-study.
2. Werling AM, Walitza S, Gerstenberger M, **Grünblatt E**, Drechsler R (2022) Media use and emotional distress under COVID-19 lockdown in a clinical sample referred for internalizing disorders: A Swiss adolescents' perspective. *J. Psych. Res.* 147:313-323. (Epub 2022 Jan 5) doi: 10.1016/j.jpsychires.2022.01.004
3. Bellenguez C, Küçükali F, Jansen I, Kleineidam L... **Grünblatt E**...et al. Ramirez A, Lambert JC (2022) New insights on the genetic etiology of Alzheimer's and related dementia. *Nature Genetics*. Accepted
4. Becker AM, Holze F, Grandinetti T, Klaiber A, Toedtli VE, Kolaczynska KE, Duthaler U, Varghese N, Eckert A, **Grünblatt E**, Liechti M (2022) Acute effects of psilocybin after escitalopram or placebo pretreatment in a randomized, double-blind, placebo-controlled, cross-over study. *Clinical Pharmacology & Therapeutics*. 111(4): 886-895 (Epub 2021 Nov 7) doi: 10.1002/cpt.2487
5. Smigielski L, Papiol S, Theodoridou A, Heekeren K, Gerstenberger M, Wortuba D, Buechler R, Hoffmann P, Herms S, Adorjan K, Anderson-Schmidt H, Budde M, Comes AL, Gade K, Heilbronner M, Heilbronner U, Kalman JL, Klöhn-Saghatolislam F, Reich-Erkelenz D, Schaupp SK, Schulte EC, Senner F, Anghelescu IG, Arolt V, Baune BT, Dannlowski U, Dietrich DE, Fallgatter AJ, Figge C, Jäger M, Juckel G, Konrad C, Nieratschker V, Reimer J, Reininghaus E, Schmauß M, Spitzer C, von Hagen M, Wiltfang J, Zimmermann J, Gryaznova A, Flatau-Nagel L, Reitt M, Meyers M, Emons B, Haußleiter IS, Lang FU, Becker T, Wigand ME, Witt SH, Degenhardt F, Forstner AJ, Rietschel M, Nöthen MM, Andlauer TFM, Rössler W, Walitza S, Falkai P\*, Schulze TG\*, **Grünblatt E\*** (2021) Polygenic risk scores across the extended psychosis spectrum. *Transl. Psych.* 11(1):600. \* Equal contribution. doi: 10.1038/s41398-021-01720-0
6. Gjoneska B, Potenza MN, Jones J, Corazza O, Hall N, Sales CMD, **Grünblatt E**, Martinotti G, Burkauskas J, Werling AM, Walitza S, Zohar J, Menchon JM, Kiraly O, Chamberlain SR, Fineberg NA, Demetrovicis Z (2021) Problematic use of the internet during the COVID-19 pandemic: Good practices and mental health recommendations *Comp. Psychiatry*. 112, 152279. <https://doi.org/10.1016/j.comppsy.2021.152279>
7. Werling AM, Walitza S, **Grünblatt E**, Drechsler R (2021) Media use before, during and after COVID-19 lockdown according to parents in a clinically referred sample in child and adolescent psychiatry: Results of an online survey in Switzerland. *Comp Psychiatry*. 109: 152260. DOI: 10.1016/j.comppsy.2021.152260

8. I de Rojas, S Moreno-Grau, N Tesí, B Grenier-Boley, V Andrade, I Jansen, N Pedersen, N Stringa, A Zettergren, I Hernández, L Montreal, C Antúnez, A Antonell, RM. Tankard, JC. Bis, R Sims, C Bellenguez, I Quintela, A González-Pérez, M Calero, E Franco-Macías, J Macías, R Blesa, L Cervera-Carles, M Menéndez-González, A Frank-García, J Royo, F Moreno, RH Vilas, M Baquero, M Diez-Fairen, Cn Lage, S Garcia-Madrona, P García-González, E Alarcón-Martín, S Valero, O Sotolongo-Grau, A Ullgren, AC. Naj, AW. Lemstra, A Benaque, A Pérez-Cordón, A Benussi, A Rabano, A Padovani, A Squassina, A de Mendonça, AA Pastor, AAL. Kok, A Meggy, A Pastor, A Espinosa, A Corma-Gómez, AM Montes, Á Sanabria, A de Stefano, A Schneider, A Haapasalo, AK Ståhlbom, A Tybjærg-Hansen, A Hartmann, A Spottke, A Corbatón-Anchuelo, A Rongve, B Borroni, B Arosio, B Nacmias, B Nordestgaard, BW. Kunkle, C Charbonnier, C Abdelnour, C Masullo, CM Rodríguez, C Muñoz-Fernandez, C Dufouil, C Graff, CB. Ferreira, C Chillotti, C Reynolds, C Fenoglio, Ce Van Broeckhoven, C Clark, C Pisanu, C Satizabal, C Holmes, D Buiza-Rueda, D Aarsland, D Rujescu, D Alcolea, D Galimberti, D Wallon, D Seripa, **E Grünblatt**, E Dardiotis, E Düzel, E Scarpini, E Conti, E Rubino, E Gelpi, E Rodriguez-Rodriguez, E Duron, E Boerwinkle, E Ferri, F Tagliavini, F Küçükali, F Pasquier, F Sanchez-Garcia, F Mangialasche, F Jessen, G Nicolas, G Selbaek, G Ortega, G Chêne, G Hadjigeorgiou, G Rossi, G Spalletta, G Giaccone, G Grande, G Binetti, G Papenberg, H Hampel, H Bailly, H Zetterberg, H Soininen, I Karlsson, I Alvarez, I Appollonio, I Giegling, I Skoog, I Saltvedt, I Rainero, IR Allende, J Hort, J Diehl-Schmid, J Van Dongen, J-S Vidal, J Lehtisalo, J Wiltfang, JQ Thomassen, J Kornhuber, J Haines, J Vogelgsang, JA. Pineda, J Fortea, J Popp, J Deckert, K Buerger, K Morgan, K Fließbach, K Sleegers, L Molina-Porcel, L Kilander, LWeinhold, L Farrer, L-S Wang, L Kleineidam, L Farotti, L Parnetti, L Tremolizzo, L Hausner, L Benussi, L Frölich, M.A Ikram, M.C Deniz-Naranjo, M Tsolaki, M Rosende-Roca, M Löwenmark, M Hulsman, M Spallazzi, M Pericak-Vance, M Esiri, MB Sánchez-Arjona, MC Dalmasso, MT Martínez-Larrad, M Arcaro, M Nöthen, M Fernández-Fuertes, M Dichgans, M Ingelsson, MJ Herrmann, M Scherer, M Vyhnaek, MH Kosmidis, M Yannakouli, M Schmid, M Ewers, M Heneka, M Wagner, M Scamosci, M Kivipelto, M Hiltunen, M Zulaica, M Alegret, M Fornage, N Roberto, N van Schoor, NM Seidu, N Banaj, N Armstrong, N Scarmeas, N Scherbaum, O Goldhardt, O Hanon, O Peters, ON Skrobot, O Quenez, O Lerch, P Bossù, P Caffarra, PD Rossi, P Sakka, P Hoffmann, P Holmans, P Fischer, P Riederer, Q Yang, R Marshall, RN Kalaria, R Mayeux, R Vandenberghe, R Cecchetti, R Ghidoni, R Frikke-Schmidt, S Sorbi, S Hagg, S Engelborghs, S Helisalmi, S Sando, S Kern, S Archetti, S Boschi, S Fostinelli, S Gil, S Mendoza, S Mead, S Ciccone, S Djurovic, S Heilmann-Heimbach, S Riedel-Heller, T Kuulasmaa, T del Ser, T Lebouvier, T Polak, T Ngandu, T Grimmer, V Bessi, V Escott-Price, V Giedraitis, V Deramecourt, W Maier, X Jian, YA.L. Pijnenburg, A Ruiz, P Kehoe, G Garcia-Ribas, P Sanchez-Juan, P Pastor, J Pérez-Tur, G Piñol-Ripoll, AL de Munain, JM García-Alberca, MJ Bullido, V Álvarez, A Lleó, LM Real, P Mir, M Medina, P Scheltens, H Holstege, M Marquié, M Saez, A Carracedo, P Amouyel, G Schellenberg, J Williams, S Seshadri, C van Duijn, K Mather, R Sánchez-Valle, M Serrano-Ríos, A Orellana, L Tarraga, K Blennow, M Huisman, O Andreassen, D Posthuma, J Clarimon, M Boada, W van der Flier, A Ramirez, J-C Lambert, S van der lee, and A Ruiz (2021) Common variants in Alzheimer's disease and risk stratification by polygenic risk scores. *Nature Communication*. 12(1): 3417. <https://doi.org/10.1038/s41467-021-22491-8>
9. Smigielski L, Wortuba D, Treyer V, Rössler J, Papiol S, Falkai P, **Grünblatt E**, Walitza S, Rössler W (2021) The interplay between postsynaptic striatal D2/3 receptor availability, adversity exposure and odd beliefs: a [11C]-raclopride PET study. *Schiz. Bullet.* 47(5):1495-1508. doi: 10.1093/schbul/sbab034.
10. Yde Ohki, C. M., Grossmann, L., Döring, C., Hoffmann, P., Herms, S., Werling, A. M., Walitza, S., **Grünblatt, E.** (2021). Generation of integration-free induced pluripotent stem cells from healthy individuals. *Stem Cell Research*. 53 (Epub 2021 Feb 24) <https://doi.org/10.1016/j.scr.2021.102269>
11. Grossmann, L., Yde Ohki, C. M., Döring, C., Hoffmann, P., Herms, S., Werling, A. M., Walitza, S., **Grünblatt, E.** (2021). Generation of integration-free induced pluripotent stem cells from ADHD patients. *Stem Cell Research*. 53 (Epub 2021 Feb 24) <https://doi.org/10.1016/j.scr.2021.102268>
12. Varinelli A, Caricasole V, Pellegrini L, Hall N, Garg K, Mpavenda D, Dell'Osso B, Albert U, the **International College of Obsessive-Compulsive Spectrum Disorders (ICOCS) Expert Survey Workgroup** and Fineberg NA (2021) Functional Interventions as Augmentation Strategies for Obsessive-Compulsive Disorder (OCD): Scoping Review and Expert Survey from the International College of Obsessive-Compulsive Spectrum Disorders (ICOCS). *Int. J. Psych. Clin. Practice*. 1-16 (Epub 2021 Jan 27). doi: 10.1080/13651501.2021.1872646
13. Burton CL, Lemire M, Xiao B, Cornfield EC, Erdman L, Bralten J, Poelmans G, Yu D, Shaheen SM, Goodale T, Sinopoli VM, **OCD Working Group of the Psychiatric Genomics Consortium**, Soreni N,

- Hanna GL, Fitzgerald KD, Rosenberg D, Nestadt G, Paterson AD, Strug L, Schachar RJ, Crosbie J, Arnold PD (2021) Genome-wide Association Study of Pediatric obsessive-compulsive traits: Shared Genetic risk between traits and disorder. *Transl. Psychiatry*. 11: 91. doi: 10.1038/s41398-020-01121-9
14. Werling AM\*, **Grünblatt E\***, Oneda B\*, Bobrowski E, Gundelfinger R, Taurines R, Romanos M, Rauch A\*, Walitza S\* (2020) High-resolution chromosomal microarray for copy number variations in high functioning autism reveals large aberration typical for intellectual-disability. *J. Neural Transm.* 127(1), 81-94 \* Contributed equally. (Epub 2019 Dec 14)
15. Kluwe-Schiavon B, Schote A, Vonmoos M, Hulka L, Preller K, Meyer J, Baumgartner M, **Grünblatt E**, Quednow B (2020) Psychiatric symptoms and expression of glucocorticoid receptor gene in cocaine users: a longitudinal study. *J Psych. Res.* 121:126-134 (Epub 2019 Nov 27).
16. Smigielski L\*, Jagannath V\*, Rössler W, Walitza S, **Grünblatt E** (2020) Epigenetic mechanisms in schizophrenia and other psychotic disorders: a systematic review of empirical human findings. *Mol. Psychiatry*. 25(8):1718-1748 \* Contributed equally. (Epub 2020 Jan 06)
17. Jagannath V\*, **Grünblatt E\***, Theodoridou A\*, Oneda B\*, Roth A, Gerstenberg M, Franscini M, Traber-Walker N, Correll CU, Heekeren K, Rössler W, Rauch A, Walitza S (2020) Rare copy number variants in individuals at clinical high risk for psychosis: Enrichment of synaptic/brain-related functional pathways. *Am. J. Med Genetics B* 183B: 140-151 \*Contributed equally. (Epub 2019 Nov 19)
18. Cross-Disorder Group of the Psychiatric Genomics Consortium. Electronic address: plee0@mgh.harvard.edu; Cross-Disorder Group of the Psychiatric Genomics Consortium. Lee PH ... **Grünblatt E**, Walitza S et al. (2019) Genomic Relationships, Novel Loci, and Pleiotropic Mechanisms across Eight Psychiatric Disorders. *Cell*. 179(7):1469-1482.e11. doi:10.1016/j.cell.2019.11.020. PubMed PMID: 31835028. (Epub 2019 Dec 12)
19. Füg F, Santos S, Haslinger C, Stoiber B, Schäffer L, **Grünblatt E**, Zimmermann R, Simoes-Wüst AP (2019) Influence of oxytocin receptor single nucleotide polymorphisms on *in vitro* contractility of human myometrium. *BMC Medical Genetics*. 20: 178
20. Franke M, Conzelmann A, **Grünblatt E**, Werling AM, Spieles H, Wewetzer C, Warnke A, Romanos M, Walitza S, Renner TJ (2019) No association of variants of the NPY-system with obsessive-compulsive disorder in children and adolescents. *Frontiers Mol. Neurosci.* 12:112 doi: 10.3389/fnmol.2019.00112
21. **Grünblatt E**, Werling AM, Roth A, Romanos M, Walitza S (2019) Association study and a systematic meta-analysis of the VNTR polymorphism in the 3'-UTR of dopamine transporter gene and attention-deficit hyperactivity disorder. *J Neural Transm.* 126(4):517-529. doi: 10.1007/s00702-019-01998-x. (Epub 2019 Mar 28)
22. Babic Perhoc A, Osmanovic Barilar J, Knezovic A, Farkas V, Bagaric R, Svarc A, **Grünblatt E**, Riederer P, Salkovic-Petrisic M, (2019) Cognitive, behavioral and metabolic effects of oral galactose treatment in the transgenic Tg2576 mice. *Neuropharmacology*. 148: 50-67 (Epub 2018 Dec 17)
23. Strobel S, **Grünblatt E**, Heinsen H, Riederer P, Espach T, Meder M, Monoranu CM (2019) Astrocytes- and microglia specific mitochondria DNA deletions levels in sporadic Alzheimer's disease. *J Alzheimer Dis.* 67(1): 149-157 (Epub 2018 Nov 22).
24. **Grünblatt E**, Nemoda Z, Werling AM, Roth A, Angyal N, Tarnok Z, Thomsen H, Peters T, Hinney A, Hebebrand J, Lesch KP, Romanos M, Walitza S (2019) The involvement of the canonical Wnt-signaling receptor LRP5 and LRP6 gene variants with ADHD and sexual dimorphism: association study and meta-analysis. *Am J Med Genet B Neuropsychiatr Genet.* 180B: 365-376 (Epub 2018 Nov 25) doi: 10.1002/ajmg.b.32695
25. Schote AB, Jäger K, Kroll SL, Vonmoos M, Hulka LM, Preller KH, Meyer J, **Grünblatt E**, Quednow BB (2019) Glucocorticoid receptor gene variants and lower expression of *NR3C1* are associated with cocaine use. *Addiction Biology*. 24: 730-742 (Epub 2018 May 15) DOI: 10.1111/adb.12632
26. Re S, Dogan AA, Ben-Shachar D, Berger G, Werling AM, Walitza S, **Grünblatt E** (2018) Improved generation of induced pluripotent stem cells from hair derived keratinocytes- a tool to study neurodevelopmental disorders as ADHD. *Frontiers in Cellular Neuroscience*. 12(321): 1-11 doi: 10.3389/fncel.2018.00321
27. Jagannath V, Gerstenberger M, Walitza S, Franscini M, Heekeren K, Rössler W, Theodoridou A, **Grünblatt E** (2018) Neuregulin (*NRG1*) gene expression predicts functional outcomes in individuals at clinical high-risk for psychosis. *Psychiatric Res.* 266:143-146. doi: 10.1016/j.psychres.2018.05.025.
28. **Grünblatt E**, Bartl J, Walitza S (2018) Methylphenidate enhances neuronal differentiation and reduces proliferation concomitant to activation of Wnt signal transduction pathways. *Translational Psychiatry*. 8:51 DOI: 10.1038/s41398-018-0096-8

29. Marinova Z, Maercker A, **Grünblatt E**, Wojdacz TK, Walitza S (2017) A pilot investigation on DNA methylation modifications associated with complex posttraumatic symptoms in elderly traumatized in childhood. *BMC Research Notes*. 10(1):752 DOI: 10.1186/s13104-017-3082-y
30. Jagannath V, Theodoridou A, Gerstenberger M, Francini M, Heekeren K, Correll CU, Rössler W, **Grünblatt E\***, Walitza S\* (2017) Prediction analysis for transition to schizophrenia in individuals at clinical high-risk for psychosis: The relationship of *DAO*, *DAOA* and *NRG1* variants with negative symptoms and cognitive deficits. *Frontiers in Psychiatry*. 8:292 \*Equal contribution. DOI: 10.3389/fpsy.2017.00292
31. **Grünblatt E**, Ruder J, Monoranu CM, Riederer P, Youdim MBH, Mandel SA (2018) Differential alterations in metabolism and proteolysis-related proteins in human Parkinson's disease substantia nigra. *Neurotox. Res*. 33(3): 560-568. (Epub 2017 Dec 7) DOI: 10.1007/s12640-017-9843-5
32. **Grünblatt E**, Oneda B, Ekici AB, Ball J, Geissler J, Uebe S, Romanos M, Rauch A, Walitza S (2017) High resolution chromosomal microarray analysis in paediatric obsessive-compulsive disorder. *BMC Medical Genomics*. 10(1):68. DOI: 10.1186/s12920-017-0299-5
33. **Grünblatt E**, Marinova Z, Roth A, Gardini E, Ball J, Geissler J, Wojdacz TK, Romanos M, Walitza S (2018) Combining genetic and epigenetic parameters of the serotonin transporter gene in obsessive-compulsive disorder. *J. Psych Res*. 96: 209-217. DOI:10.1016/i.jpsychires.2017.10.010
34. Jagannath V, Brotzakis ZF, Parrinello M, Walitza S, **Grünblatt E** (2017) Controversial effects of D-amino acid oxidase activator (DAOA)/G72 on D-amino acid oxidase (DAO) activity in human neuronal, astrocyte, and kidney cell lines: The N-methyl D-aspartate (NMDA) receptor hypofunction point of view. *Frontiers in Molecular Neuroscience*. 10:342.
35. Scholz CJ, Weber H, Jungwirth S, Danielczyk W, Reif A, Tragl KH, Fischer P, Riederer P, Deckert J, **Grünblatt E** (2018) Explorative results from multistep screening for potential genetic risk loci of Alzheimer's disease in the longitudinal VITA study cohort. *J Neural Transm*. 125: 77-87 (Epub 2017 October 12)
36. Jagannath V, Gerstenberger M, Correll CU, Walitza S, **Grünblatt E** (2018) A systematic meta-analysis of the association of Neuregulin 1 (NRG1), D-amino acid oxidase (DAO), and DAO activator (DAOA)/G72 polymorphisms with schizophrenia. *J Neural Transm*. 125(1):89-102 (Epub 2017 Sept 1)
37. Marinova Z, Walitza S, **Grünblatt E** (2018) Effects of oxytocin and arginine vasopressin on the proliferation and differentiation of a serotonergic cell line. *J Neural Transm*. 125(1):103-106 (Epub 2017 August 18)
38. Noh HJ, Tang R, Flannick J, O'Dushlaine C, Swofford R, Howrigan D, Genereux D, Johnson J, van Grootheest G, **Grünblatt E**, Andersson E, Djurfeldt D, Patel P, Koltoukian M, Hultman C, Pato M, Pato C, Rasmussen S, Jenike M, Hanna G, Stewart E, Knowles J, Ruhmann S, Grabe H, Wagner M, Rück C, Mathews C, Walitza S, Cath D, Feng G, Karlsson E, Lindblad-Toh K (2017) Integrating evolutionary and regulatory information with multispecies approach implicates genes and pathways in obsessive-compulsive disorder. *Nat. Commun*. 8 (1): 744. DOI:10.1038/s41467-017-00831-x
39. Bartl J, Palazzesi F, Parrinello M, Hommer L, Riederer P, Walitza S, **Grünblatt E** (2017) The impact of methylphenidate and its enantiomers on dopamine synthesis and metabolism in vitro. *Progress in Neuro-Psychopharmacology & Biological. Psych*. 79: 281-288.
40. Dolder PC, **Grünblatt E**, Mueller F, Borgwardt S, Liechti ME (2017) A single dose of LSD does not alter gene expression of the serotonin 2A receptor gene (HTR2A) or early growth response genes (EGR1-3) in healthy subjects. *Frontiers in Pharmacology, Neuropharmacology*. 8: 423 (doi: 10.3389/fphar.2017.00423)
41. International Obsessive Compulsive Disorder Foundation Genetics Collaborative (IOCDF-GC) and OCD Collaborative Genetics Association Studies (OC GAS),... **Grünblatt E**, Walitza S, et al. Knowles JA, Nestadt G (2018) Revealing the complex genetic architecture of obsessive-compulsive disorder using meta-analysis. *Mol. Psychiatry*. 23(5): 1181-1188 (Epub 2017 August 1) doi: 10.1038/mp.2017.154
42. Müller, T, Riederer P, **Grünblatt E** (2017) Determination of MAO-A and -B activity in long-term treated patients with Parkinson's disease. *Clin. Neuropharmacol*. 40(5): 208-211
43. Jagannath V, Marinova Z, Monoranu CM, Walitza S, **Grünblatt E** (2017) Expression of D-amino acid oxidase (DAO/DAAO) and D-amino acid oxidase activator (DAOA/G72) during Development and Aging in the Human Post-Mortem Brain. *Frontiers in Neuroanatomy*. 11:31.
44. Müller T, Riederer P, **Grünblatt E** (2017) Simultaneous determination of MAO-A and -B activity following first time intake of an irreversible MAO-B inhibitor in patients with Parkinson's disease. *J Neural Transm*. 124(6): 745-748. (Epub 2017 March 15)

45. Marinova Z, Walitza S, **Grünblatt E** (2017) The hallucinogen 2,5-dimethoxy-4-iodoamphetamine hydrochloride activates neurotrophin receptors in a neuronal cell line and promotes neurites extension. *J Neural Transm.* 124(6): 749-759 (Epub 2017 March 18)
46. Marinova Z, Maercker A, Küffer A, Robinson MD, Wojdacz TK, Walitza S, **Grünblatt E**, Burri A (2017) DNA methylation profiles of elderly individuals subjected to indentured childhood labor and trauma. *BMC Medical Genetics.* 18: 21; DOI: 10.1186/s12881-017-0370-2.
47. Havranek MM, Hulka LM, Tasiudi E, Vonmoos M, Mössner R, Seifritz E, Baumgarnter MR, **Grünblatt E**, Quednow BB (2017)  $\alpha$ 2A-adrenergic receptor polymorphisms and mRNA expression levels are associated with delay discounting in cocaine users. *Addiction Biology.* 22(2): 561-569 (Epub 2015 Nov 8) DOI:10.1111/adb.12324.
48. Werling AM, Bobrowski E, Taurines R, Gundelfinger R, Romanos M, **Grünblatt E\***, Walitza S\* (2016) CNTNAP2 gene in high functioning autism: No association according to family and meta-analysis approaches. *J Neural Transm.* 123(3):35363 (Epub 2015 Nov 11). (\* Both authors contributed equally)
49. **Grünblatt E**, Bartl J, Iuhos DI, Knezovic A, Trulja V, Riederer P, Walitza S, Salkovic-Petrisic M (2015) Characterization of cognitive deficits in spontaneously hypertensive rats, accompanied by brain insulin receptor dysfunction. *J. Mol. Psych.* 3(1): 6. DOI:10.1186/s40303-015-0012-6
50. Havranek MM, Vonmoos M, Müller CP, Büetiger JR, Tasiudi E, Hulk LM, Preller KH, Mössner R, **Grünblatt E**, Seifritz E, Quednow BB (2015) Serotonin transporter and tryptophan hydroxylase gene variations mediate working memory deficits of cocaine users. *Neuropsychopharmacology.* 40(13): 2929-37. (Epub 2015 May 27). DOI: 10.1038/npp.2015.146
51. Strobel S\*, **Grünblatt E\***, Riederer P, Heinsen H, Arzberger T, Al-Sarraj S, Troakes C, Ferrer I, Monoranu CM (2015) Changes in the expression of genes related to neuroinflammation over the course of sporadic Alzheimer's disease progression: CX3CL1, TREM2, and PPARgamma. *J Neural Transm.* 122(7): 1069-76 (Epub 2015 Jan 18). (\* Both authors contributed equally)
52. Segura M, Pedreno C, Obiols J, Taurines R, Pamias M, **Grünblatt E**, Gella A (2015) Neurotrophin blood based gene expression and social cognition analysis in patients with Autism Spectrum Disorder. *Neurogenetics.* 16(2): 123-31. (Epub 2014 Dec 24).
53. Barilar Osmanovic J, Knezovic A, **Grünblatt E**, Riederer P, Salkovic-Petrisic M. (2015) Nine-month follow-up of the insulin receptor signalling cascade in the brain of streptozotocin in rat model of sporadic Alzheimer's disease. *J Neural Transm.* 122(4): 565-76. (Epub 2014 Dec 12).
54. Durrenberger PF, Fernando FS, Kashefi SN, Bonnert TP, Seilhean D, Nait-Oumesmar B, Schmitt A, Gebicke-Haerter PJ, Falkai P, **Grünblatt E**, Palkovits M, Arzberger T, Kretschmar H, Dexter DT, Reynolds R (2014) Common mechanisms in neurodegeneration and neuroinflammation: a BrainNet Europe gene expression microarray study. *J Neural Transm.* 122(7): 1055-68 (Epub 2014 Aug 13).
55. Yu D, Mathews CA, Scharf JM, Neale BM, Davis LK, Gamazon ER, Derks EM, Evans P, Edlund CK, Crane J, Fagerness JA, Osiecki L, Gallagher P, Gerber G, Haddad S, Illmann C, McGrath LM, Mayerfeld C, Arepalli S, Barlassina C, Barr CL, Bellodi L, Benarroch F, Berrio GB, Bienvenu OJ, Black D, Bloch MH, Brentani H, Bruun RD, Budman CL, Camarena B, Campbell DD, Cappi C, Silgado JCC, Cavallini MC, Chavira DA, Chouinard S, Cook EH, Cookson MR, Coric V, Cullen B, Cusi D, Delorme R, Denys D, Dion Y, Eapen V, Egberts K, Falkai P, Fernandez T, Fournier E, Garrido H, Geller D, Gilbert D, Girard SL, Grabe HJ, Grados MA, Greenberg BD, Gross-Tsur V, **Grünblatt E**, Hardy J, Heiman GA, Hemmings SMJ, Herrera LD, Hezel MD, Hoekstra PJ, Jankovic J, Kennedy ML, King RA, Konkashbaev AI, Kremeyer B, Kurlan R, Lanzagorta N, Leboyer M, Leckman JF, Lennertz L, Liu C, Lochner C, Lowe TL, Lupoli S, Macciardi F, Maier W, Manunta P, Marconi M, McCracken JT, Restrepo SCM, Moessner R, Moorjani P, Morgan J, Muller H, Murphy DL, Naarden AL, Ochoa WC, Ophoff RA, Pakstis AJ, Pato MT, Pato CN, Piacentini J, Pittenger C, Pollak Y, Rauch SL, Renner T, Reus VI, Richter MA, Riddle MA, Robertson MM, Romero R, Rosario MC, Rosenberg D, Ruhrmann S, Sabatti C, Salvi E, Sampaio AS, Samuels J, Sandor P, Service SK, Sheppard B, Singer HS, Smit JH, Stein DJ, Strengman E, Tischfield JA, Turiel M, Duarte AVV, Vallada H, Veenstra-VanderWeele J, Walitza S, Walkup J, Wang Y, Weale M, Weiss R, Wendland JR, Westenberg HGM, Yao Y, Hounie AG, Miguel EC, Nicolini H, Wagner M, Ruiz-Linares A, Cath DC, McMahon W, Posthuma D, Oostra BA, Nestadt G, Rouleau GA, Purcell S, Jenike MA, Heutink P, Hanna GL, Conti DV, Arnold PD, Freimer N, Stewart SE, Knowles JA, Cox NJ, Pauls DL (2015) Cross-Disorder Genome-wide analyses suggest separate genetic contributions to Tourette syndrome and obsessive-compulsive disorder. *Am. J Psychiatry.* 171(1): 82-93 DOI: 10.1176/appi.ajp.2014.13101306 (Epub 2014 Aug 26).

56. McGrath LM, Yu D, Marshall C, Davis LK, Thiruvahindrapuram B, Li B, Cappi C, Gerber G, Wolf A, Schroeder FA, Osiecki L, O'Dushlaine C, Kirby A, Illmann C, Haddad S, Gallagher P, Fagerness JA, Barr CL, Bellodi L, Benarroch F, Bienvenu OJ, Black DW, Bloch MH, Bruun RD, Budman CL, Camarena B, Cath DC, Cavallini MC, Chouinard S, Coric V, Cullen B, Delorme R, Denys D, Derks EM, Dion Y, Rosário MC, Eapen V, Evans P, Falkai P, Fernandez T, Garrido H, Geller D, Grabe HJ, Grados MA, Greenberg BD, Gross-Tsur V, **Grünblatt E**, Heiman GA, Hemmings SMJ, Herrera LD, Hounie AG, Jankovic J, Kennedy JL, King RA, Kurlan R, Lanzagorta N, Leboyer M, Leckman JF, Lennertz L, Lochner C, Lowe TL, Lyon GJ, Macciardi F, Maier W, McCracken JT, McMahon W, Murphy DL, Naarden AL, Neale BM, Nurmi E, Pakstis AJ, Pato MT, Pato CN, Piacentini J, Pittenger C, Pollak Y, Reus VI, Richter MA, Riddle MA, Robertson MM, Rosenberg D, Rouleau GA, Ruhrmann S, Sampaio AS, Samuels J, Sandor P, Sheppard P, Singer HS, Smit JH, Stein DJ, Tischfield JA, Vallada H, Veenstra-VanderWeele J, Walitza S, Wang Y, Wendland JR, Yao Shugart Y, Miguel EC, Nicolini H, Oostra BA, Moessner R, Wagner M, Ruiz-Linares A, Heutink P, Nestadt G, Freimer N, Petryshen T, Posthuma D, Jenike, MD MA, Cox NJ, Hanna GL, Brentani H, Scherer SW, Arnold PD, Stewart SE, Mathews CA, Knowles JA, Cook EH, Pauls DL, Wang K, Scharf JM (2014) Copy number variation in obsessive-compulsive disorder and Tourette syndrome: A cross-disorder analysis study. *J Am Acad Child Adolesc Psychiatry* 53(8): 910-9 (Epub 2014 June 24).
57. Bielas H, Arck P, Bruenahl CA, Walitza S, **Grünblatt E** (2014) Prenatal stress increases the striatal and hippocampal expression of correlating c-FOS and serotonin transporter in murine offspring. *Int. J Dev. Neurosci.* 38C: 30-35. DOI: 10.1016/j.ijdevneu.2014.07.006 (Epub 2014 Aug 4)
58. Adamsen D, Ramaekers V, Ho HTB, Britschgi C, Rüfenacht V, Meili D, Bobrowski E, Philippe P, Nava C, Maldergem LV, Bruggmann R, Walitza S, Wang J, **Grünblatt E**, Thöny B (2014) Autism spectrum disorder associated with low serotonin in CSF and mutations in the SLC29A4 plasma membrane monoamine transporter (PMAT) gene. *Mol Autism.* 5(1): 43. DOI:10.1186/2040-2392-5-43
59. Walitza S, Marinova Z, **Grünblatt E**, Lazic SE, Remschmidt H, Vloet TD, Wendland JR (2014) Trio study and meta-analysis support the association of genetic variation at the serotonin transporter with early-onset obsessive-compulsive disorder. *Neurosc. Lett.* 580: 100-103. DOI: 10.1016/j.neulet.2014.07.038 (Epub 2014 Aug 2)
60. Marinova Z, Monoranu CM, Fetz S, Walitza S, **Grünblatt E** (2015) Region-specific regulation of the serotonin 2A receptor expression in development and aging in postmortem human brain. *Neuropathol. Appl Neurobiol.* 41(4): 520-32. DOI: 10.1111/nan.12167 (Epub 2014 July 8).
61. Taurines R, Segura M, Schenkelmann M, Albantakis L, **Grünblatt E**, Walitza S, Jans T, Lyttwin B, Haberhausen M, Theisen FM, Martin B, Briegel W, Thome J, Schwenck C, Romanos M, Gerlach M (2014) Altered peripheral BDNF mRNA expression and BDNF protein concentrations in blood of children and adolescents with autism spectrum disorder. *J. Neural Transm.* 121(9):1117-28. (Epub 2014 Feb 6).
62. Nyffeler J, Walitza S, Bobrowski E, Gundelfinger R, **Grünblatt E** (2014) Association study in siblings and case-controls of serotonin- and oxytocin-related genes with high functioning autism. *J Mol Psych.* 2:1-9 (doi:10.1186/2049-9256-2-1)
63. Scholz CJ, Jungwirth S, Danielczyk W, Weber H, Wichart I, Tragl KH, Fischer P, Riederer P, Deckert J, **Grünblatt E**. (2014) Investigation of association of serotonin transporter and monoamine oxidase-A genes with Alzheimer's disease and depression in the VITA study cohort: A 90-months longitudinal study. *Am J Med Genet B Neuropsychiatr Genet.* 165(2): 184-91 (Epub 2014 Jan 17).
64. Gerschütz A, Heinsen H, **Grünblatt E**, Wagner AK, Bartl J, Meissner C, Fallgatter AJ, Al-Sarraj S, Troakes C, Ferrer I, Arzberger T, Deckert J, Riederer P, Fischer M, Tatschner T, Monoranu CM (2014) Neuron-specific alterations in signal transduction pathways associated with Alzheimer's disease. *J. Alzheimer's Dis.* 40(1): 135-42 (Epub 2013 Dec. 13).
65. Bartl J, Walitza S, **Grünblatt E** (2014) Enhancement of cell viability after treatment with polyunsaturated fatty acids. *Neurosc. Lett.* 559: 56-60 (Epub 2013 Nov 21).
66. Bartl J, Müller T, **Grünblatt E**, Gerlach M, Riederer P (2013) Chronic monoamine oxidase-B inhibitor treatment blocks monoamine oxidase-A enzyme activity. *J. Neural Transm.* 121(4): 379-383 (Epub 2013 Nov. 23).
67. Michel TM, Käsbauer L, Gsell W, Jecel J, Sheldrick AJ, Cortese M, Nickl-Jockschat T, **Grünblatt E**, Riederer P (2014) Aldehyde dehydrogenase 2 in sporadic Parkinson's disease. *Parkinsonism & Related Disorders.* Vol. 20 Suppl. 1: S68-S72
68. Gerschütz A, Heinsen H, **Grünblatt E**, Wagner AK, Bartl J, Meissner C, Fallgatter AJ, Al-Sarraj S, Troakes C, Ferrer I, Arzberger T, Deckert J, Riederer P, Fischer M, Tatschner T, Monoranu CM (2013)

- Neuron-specific mitochondrial DNA deletion levels in sporadic Alzheimer's Disease. *Curr. Alzheimer Res.* 10(10): 1041-6 (Epub 2013 Oct 23).
69. Wyss C, Hitz K, Hengartner MP, Theodoridou A, Obermann C, Uhl I, Roser P, **Grünblatt E**, Seifritz E, Juckel G, Kawohl W (2013) The loudness dependence of auditory evoked potentials (LDAEP) as an indicator of serotonergic dysfunction in patients with predominant Schizophrenic negative symptoms. *PLOS One*, 8(7): e68650.
70. Marinova Z, Walitza S, **Grünblatt E** (2013) 5-HT<sub>2A</sub> serotonin receptor agonist DOI alleviates cytotoxicity in neuroblastoma cells: role of the ERK pathway. *Progress in Neuro-Psychopharmacology & Biological.* 44C:64-72. (Epub 2013 Feb 1).
71. Bartl J, Mori T, Riederer P, Ozawa H, **Grünblatt E** (2013) Methylphenidate enhances neuronal stem cell differentiation. *J. Mol. Psych.* 1: 5
72. Durrenberger PF, Fernando FS, Kashefi SN, Bonnert TP, Ferrer I, Seilhean D, Nait-Oumesmar B, Schmitt A, Gebicke-Haerter PJ, Falkai P, **Grünblatt E**, Palkovits M, Arzberger T, Kretschmar H, Dexter DT and Reynolds R (2012) Selection of novel reference genes for use in the human central nervous system: a BrainNet Europe Study. *Acta Neuropathologica.* 124(6): 893-903
73. Bartl J, Meyer A, Brendler S, Riederer P, **Grünblatt E** (2013) Different effects of soluble and aggregated Amyloid-beta(42) on gene/protein expression and enzyme activity involved in insulin and APP pathways. *J Neural Transm.* 120(1):113-20. (Epub 2012 July 11)
74. Molochnikov L, Rabey JM, Dobronevsky E, Bonucelli U, Ceravolo R, Frosini D, **Grünblatt E**, Riederer P, Jacob C, Peretz JA, Bashenko Y, Youdim MBH, Mandel SA (2012) A molecular signature in blood identifies early Parkinson's disease. *Molecular Neurodegeneration.* 7:26. doi: 10.1186/1750-1326-7-26.
75. **Grünblatt E**, Geißler J, Jacob CP, Renner T, Müller M, Bartl J, Gross-Lesch S, Riederer P, Lesch KP, Walitza S, Gerlach M, Schmitt A (2012) Pilot study: potential transcription markers for adult attention-deficit hyperactivity disorder in whole blood. *J ADHD.* 4(2):77-84.
76. Durrenberger P, **Grünblatt E**, Fernando F, Monoranu CM, Evans J, Riederer P, Reynolds R and Dexter DT (2012) Inflammatory pathways in Parkinson's disease – a BNE microarray study. *Parkinson's disease.* Article ID 214714. doi:10.1155/2012/214714.
77. Bartl J, Monoranu C-M, Wagner A-K, Kolter J, Riederer P, **Grünblatt E** (2013) Alzheimer's disease and Type 2 Diabetes: two diseases, one common link? *World J Biol. Psych.* 14(3): 233-40 (Epub 2012 Feb. 14)
78. Walitza S, Sabanés Bové D, Romanos M, Renner T, Held L, Simons M, Wewetzer C, Fleischhaker C, Remschmidt H, Warnke A, **Grünblatt E** (2012) Pilot study on HTR2A promoter polymorphism, – 1438G/A (rs6311) and a nearby copy number variation showed association with onset and severity in early-onset obsessive-compulsive disorder. *J Neural Transm.* 119(4): 507-515.
79. Bartl J, Scholz CJ, Hinterberger M, Jungwirth S, Wichart I, Rainer MK, Kneitz S, Danielczyk W, Tragl KH, Fischer P, Riederer P, **Grünblatt E** (2011) Disorder-specific effects of polymorphisms at opposing ends of the Insulin Degrading Enzyme gene. *BMC Med Genet.* 12(1):151.
80. Taurines R, **Grünblatt E**, Schenkelmann M, Schwenck C, Albantakis L, Reefschläger L, Walitza S, Renner T, Gerlach M, Thome J, Romanos M (2011) Altered mRNA expression of monoaminergic candidate genes in the blood of children with attention deficit hyperactivity disorder and autism spectrum disorder. *World J Biol Psychiatry.* Suppl. 1:104-8.
81. **Grünblatt E**, Reif A, Jungwirth S, Galimberti D, Weber H, Scarpini E, Sauer C, Wichart I, Rainer MK, Huber K, Danielczyk W, Tragl KH, Deckert J, Fischer P, Riederer P (2011) Genetic variation in the choline O-acetyltransferase gene in depression and Alzheimer's disease: the VITA and Milano studies. *J Psych. Res.* 45(9): 1250-1256.
82. **Grünblatt E**, Schmidt WJ, Scheller DKA, Riederer P, Gerlach M (2011) Transcriptional alterations under continuous or pulsatile dopaminergic treatment in dyskinetic rats. *J. Neural Transm.* 118(12):1717-25. (Epub Dec 25).
83. Reif A\*, **Grünblatt E\***, Herterich S, Wichart I, Rainer MK, Jungwirth S, Danielczyk W, Deckert J, Tragl KH, Riederer P, Fischer P (2011) Association of functional NOS1 promoter repeat with Alzheimer's disease in the VITA cohort. *J Alzheimer Dis.* 23(2):327-33 (\* Both authors contributed equally)
84. Michel TM, Sheldrick AJ, Camara S, **Grünblatt E**, Schneider F, Riederer P (2011) Alteration of the pro-oxidant xanthine oxidase (XO) in the thalamus and occipital cortex of patients with schizophrenia. *The World J Biol. Psych.* 12(8): 588-97.
85. Bartl J, Link P, Schlosser C, Gerlach M, Schmitt A, Walitza S, Riederer P, **Grünblatt E** (2010) Effects of methylphenidate: The cellular point of view. *Atten Defic Hyperact Disord.* 2(4): 225-232.

86. **Grünblatt E**, Zehetmayer S, Jacob CP, Müller T, Jost WH, Riederer O (2010) Pilot study: Peripheral biomarkers for diagnosing sporadic Parkinson's disease. *J. Neural Transm.* 117(12):1387-93.
87. Zheng B, Liao Z, Locascio JJ, Lesniak KA, Roderick SS, Watt ML, Eklund AC, Zhang-James Y, Kim PD, Hauser MA, **Grünblatt E**, Moran LB, Mandel SA, Riederer P, Miller RM, Federoff HJ, Wüllner U, Papapetropoulos S, Youdim MBH, Cantuti-Castelvetri I, Young AB, Vance JM, Davis RL, Hedreen JC, Adler CH, Beach TG, Graeber MB, Middleton FA, Rochet JC, Scherzer CR for the Global PD Gene Expression (GPEX) Consortium (2010) PGC-1 $\alpha$  potential therapeutic target for early intervention in Parkinson's disease. *Science Transl. Med.* 2(52): 52-73.
88. **Grünblatt E**, Proft F, Apfelbacher M, Deckert J, Roggendorf W, Riederer P, Monoranu CM (2010) Brain tryptophan rather than pH-value is altered as consequence of artificial postmortem interval and storage conditions. *Neurochemistry Int.* 57(7):819-22.
89. Monoranu CM<sup>+</sup>, **Grünblatt E**<sup>+</sup>, Bartl J, Meyer A, Apfelbacher M, Keller D, Michel TM, Al-Saraj S, Schmitt A, Falkai P, Roggendorf W, Deckert J, Ferrer I, Riederer P (2011) Methyl- and Acetyltransferases are stable epigenetic markers postmortem. *Cell & Tissue Banking.* 12(4): 289-97 [Epub ahead of print 2010 Jul 23] (<sup>+</sup> Both authors contributed equally).
90. Michel TM, Gsell W, Geuder J, Frangou S, Durany N, Kircher T, Sheldrick AJ, Tatschner T, Schneider F, Riederer P, **Grünblatt E** (2010) Can enzyme kinetics of prooxidants teach us a lesson about the treatment of Alzheimer's disease: A pilot post-mortem study. *World J Biol Psychiatry.* 1(4): 677-81.
91. Michel TM, Camara S, Tatschner T, Frangou S, Sheldrick AJ, Riederer P, **Grünblatt E** (2010) Increased xanthine oxidase in the thalamus and putamen in depression. *World J Biol. Psych.* 11(2 Pt 2):314-20.
92. Michel TM, Gsell W, Käsbauer L, Tatschner T, Sheldrick AJ, Neuner I, Schneider F, **Grünblatt E**, Riederer P. (2010) Increased activity of mitochondrial aldehyde dehydrogenase (ALDH) in the putamen of individuals with Alzheimer's disease - a human postmortem study. *J. Alzheimer Dis.* 19(4):1295-1301.
93. Osmanovic J, Plaschke K, Salkovic-Petrisic M, **Grünblatt E**, Riederer P, Hoyer S (2010) Chronic exogenous corticosterone administration generates an insulin-resistant brain state in rats. *Stress.* 13(2):123-31.
94. **Grünblatt E**, Monoranu CM, Apfelbacher M, Keller D, Michel TM, Alafuzoff I, Ferrer I, Al-Saraj S, Keyvani K, Schmitt A, Falkai P, Schittenhelm J, McLean C, Halliday GM, Harper C, Deckert J, Roggendorf W, Riederer P (2009) Tryptophan is a marker of human postmortem brain tissue quality. *J. Neurochem.* 110: 1400-1408.
95. **Grünblatt E**, Bartl J, Zehetmayer S, Ringel TM, Bauer P, Riederer P, Jacob CP (2009) Gene expression as peripheral biomarkers for sporadic Alzheimer's disease. *J. Alzheimer Dis.* 16(3):627-34.
96. Monoranu CM, Apfelbacher M, **Grünblatt E**, Puppe B, Alafuzoff I, Ferrer I, Al-Saraj S, Keyvani K, Schmitt A, Falkai P, Schittenhelm J, Halliday G, Kril J, Harper C, Riederer P, Roggendorf W (2009) pH measurement as quality control on human postmortem brain tissue: A Study of the Brain Net Europe Consortium. *Neuropath. Appl. Neurobiol.* 35(3):329-37.
97. **Grünblatt E**, Zehetmayer S, Bartl J, Löffler C, Wichart I, Rainer MK, Jungwirth S, Bauer P, Danielczyk W, Tragl KH, Riederer P, Fischer P (2009) Genetic risk factors and markers for Alzheimer's disease and/or depression in the VITA study. *J Psych. Res.* 43(3):298-308.
98. Michel TM, Frangou S, Camara S, Thiemeyer D, Jecel J, Tatschner T, Zoehling R, **Grünblatt E** (2008) Altered glial cell line-derived neurotrophic factor (GDNF) concentrations in the brain of patients with depressive disorder: A comparative post-mortem study. *Eur. Psych.* 23(6):413-20.
99. Schmidt WJ, Lebsanft H, Heindl M, Riederer P, **Grünblatt E**, Gerlach M, Scheller DK (2008) Continuous versus pulsatile administration of rotigotine in 6-OHDA-lesioned rats: contralateral rotations and abnormal involuntary movements *J. Neural Transm.* 115(10):1385-92.
100. **Grünblatt E**, Zander N, Bartl J, Jie L, Monoranu C.M, Arzberger T, Rivka R, Roggendorf W, Gerlach M, Riederer P (2007) Comparison analysis of gene expression patterns between sporadic Alzheimer's and Parkinson's disease. *J. Alzheimer Dis.* 12(4): 291-311.
101. Jacob CP, Koutsilieri E, Bartl J, Neuen-Jacob E, Arzberger T, Zander N, Ravid R, Roggendorf W, Riederer P, **Grünblatt E** (2007) Alterations in expression of glutamatergic transporters and receptors in sporadic Alzheimer's Disease *J. Alzheimer Dis.* 11(1):97-116.
102. **Grünblatt E**, Salkovic-Petrisic M, Osmanovic J, Riederer P, Hoyer S (2007) Brain insulin system dysfunction in streptozotocin intracerebroventricularly treated rats generates hyperphosphorylated tau protein. *J. Neurochem.* 101(3): 757-70.
103. Moussa B.H.Y, **Grünblatt E**, Mandel S (2007) The copper chelator, D-penicillamine, does not attenuate MPTP induced dopamine depletion in mice. *J. Neural. Transm.* 114(2):205-9.



104. Luckhaus C, Spiegler C, Ibach B, Fischer P, Wichart I, Sterba N, Gatterer G, Rainer M, Jungwirth S, Huber K, Tragl KH, **Grünblatt E**, Riederer P, Sand P (2006) Estrogen Receptor  $\beta$  Gene (*ESR $\beta$* ) 3'-UTR Variants in Alzheimer Disease. *Alzheimer Disease & Associated Disorders*. 20(4):322-323.
105. Mehler-Wex C. \*, **Grünblatt E.** \*, Zeiske S, Gille G, Rausch D., Warnke A , Gerlach M (2006) Microarray analyses reveals distinct gene expression patterns in the mouse cortex following chronic neuroleptic and stimulant treatment: implications for body weight changes. *J. Neural Transm.* (\* Both authors contributed equally), 113: 1383-1393.
106. **Grünblatt E.**, Löffler C, Zehetmayer S, Jungwirth S, Tragl KH, Riederer P\*, Fischer P\* (2006) Association study of the 5-HTTLPR polymorphism and depression in non-demented subjects of age 75 from the VITA study. *J. Clinic. Psych.* (\* Both authors contributed equally) 67(9): 1373-1378.
107. **Grünblatt E**, Koutsilieri E, Hoyer S, Riederer P (2006) Gene expression alterations in brain areas of intracerebroventricular streptozotocin treated rat. *J. Alzheimer Dis.* 9 (3) 261-71.
108. Fischer P, **Grünblatt E**, Pietschmann P, Tragl K-H (2006) Serotonin transporter polymorphism and LDL-Cholesterol. *Mol. Psychiatry*. 11: 707-709.
109. **Grünblatt E**, Hupp E, Bambula M, Zehetmayer S, Jungwirth S, Tragl KH, Fischer P, Riederer P (2006) Association study of BDNF and CNTF polymorphism to depression in non-demented subjects of the VITA" study. *J. Affective Disorders*. 96:111-116.
110. **Grünblatt E**, Schlößer R, Fischer P, Fischer MO, Li J, Koutsilieri E, Wichart I, Sterba N, Rujescu D, Möller HJ, Adamcyk W, Dittrich B, Müller F, Oberegger K, Gatterer G, Jellinger KJ, Mostafaie N, Jungwirth S, Huber K, Tragl KH, Danielczyk W, Riederer P (2005) Oxidative stress related factors related markers in the "VITA" and the Centenarian projects. *Neurobiol. Aging*. 26(4): 429-438.
111. Scheller C, Sopper S, Jenuwein M, Neuen-Jacob E, Tatschner T, Stahl-Hennig C, **Grünblatt E**, ter Meulen V, Riederer P, Koutsilieri E (2005) Early impairment in dopaminergic neurotransmission in brains of SIV-infected rhesus monkeys due to microglia activation. *J. Neurochem*. 95(2):377-87.
112. **Grünblatt E.**, Hoyer S., Riederer P. (2004) Gene expression profile in streptozotocin rat model for sporadic Alzheimer's disease. *J. Neural Transm.* 111(3): 367-386.
113. **Grünblatt E.**, Mandel S., Hirsch J.J., Zeligson S., Amariglio N., Rechavi G, Li J., Ravid R., Roggendorf W., Riederer P., Youdim M.B.H. (2004) Genomic profiling of Parkinsonian substantia nigra pars compacta; Alterations in Ubiquitin-proteasome, heat shock protein, iron regulated proteins, cell adhesion/cellular matrix and vesicle trafficking genes. *J. Neural Transm.* 111(12):1543-73.
114. Mandel S., **Grünblatt E.**, Maor G. and Youdim M.B.H. (2002) Early and late gene changes in MPTP mice model of Parkinson's disease employing cDNA microarray. *Neurochem Res*. 2002 Oct; 27(10):1231-43.
115. **Grünblatt E.**, Mandel S., Maor G., and Youdim M.B.H. (2001) Effects of R-apomorphine and S-apomorphine on MPTP-induced striatal dopamine neuronal loss. *J. Neurochem*. 77(1): 146-156.
116. **Grünblatt E.**, Mandel S., Maor G., and Youdim M.B.H. (2001) Gene expression analysis in MPTP model of Parkinson's disease using cDNA microarray. *J. Neurochem*. 78(1): 1-12.
117. **Grünblatt E.**, Mandel S., Berkuzki T. and Youdim M.B.H. (1999) Apomorphine protects against MPTP induced neurotoxicity in mice *Mov. Disord*. 14: 612-618.

### III. Case report (peer-review)

1. **Grünblatt E**, Tschakarjan S, Brezinka V, Walitza S (2014) Extraordinarily Fast Response to Low-Dose Sertraline in a Child with Severe Obsessive-Compulsive Disorder and High Functioning Serotonin Transporter Genotype. *J Child Adol. Psychopharmacol*. 24(2): 102-104 (Epub 2014 Jan 16)

### IV. Reviews (peer-review)

1. Yde Ohki CM, Grossmann L, Alber E, Dwiwedi T, Berger G, Werling AM, Walitza S, **Grünblatt E** (2020) The stress-wnt-signaling axis: a hypothesis for attention-deficit hyperactivity disorder and therapy approaches. *Translational Psychiatry* 10:315. doi: 10.1038/s41398-020-00999-9
2. Fineberg, N. A., Hollander, E., Pallanti, S., Walitza, S., **Grünblatt, E.**, Dell'Osso, B. M., Albert, U., Geller, D. A., Brakoulias, V., Janardhan Reddy, Y. C., Arumugham, S. S., Shavitt, R. G., Drummond, L., Grancini, B., De Carlo, V., Cinosi, E., Chamberlain, S. R., Ioannidis, K., Rodriguez, C. I., Garg, K., ... Menchon, J. M. (2020). Clinical advances in obsessive-compulsive disorder: a position statement by the International College of Obsessive-Compulsive Spectrum Disorders. *International clinical psychopharmacology*. 35(4):173-193 10.1097/YIC.0000000000000314.

3. Király O, Potenza MN, Stein DJ, King DL, Hodgins DC, Saunders JB, Griffiths MD, Gjoneska B, Billieux J, Brand M, Abbott MW, Chamberlain SR, Corazza O, Burkauskas J, Sales CM, Montag C, Lochner C, **Grünblatt E**, Wegmann E, Martinotti G, Lee HK, Rumpf HJ, Castro-Calvo J, Rahimi-Movaghar A, Higuchi S, Menchon JM, Zohar J, Pellegrini L, Walitza S, Fineberg NA, Demetrovics Z (2020) Preventing problematic internet use during the COVID-19 pandemic: consensus guidance. *Comp. Psychiatry*. 100:152180 doi: 10.1016/j.comppsy.2020.152180
4. Van den Heuvel O, Boedhoe PSW, Bertolin S, Bruin WB, Francks C, Ivanov I, Jahanshad N, Kong XZ, Kwon JS, O'Neill J, Paus T, Patel Y, Piras F, Schmaal L, Soriano-Mas C, Spalletta G, van Wingen GA, Yun JY, Vriend C, Simpson HB, van Rooij D, Hoexter MQ, Hoogman M, Buitelaar JK, Arnold P, Beucke JC, Benedetti F, Bollettini I, Bose A, Brennan BP, De Nadai AS, Fitzgerald K, Gruner P, **Grünblatt E**, Hirano Y, Huyser C, James A, Koch K, Kvale G, Lazaro L, Lochner C, Marsh R, Mataix-Cols D, Morgado P, Nakamae T, Nakao T, Narayanaswamy JC, Nurmi E, Pittenger C, Reddy J, Sato JR, Soreni N, Stewart SE, Taylor SF, Tolin D, Thomopoulos SI, Veltman DJ, Venkatasubramanian G, Walitza S, Thompson PM, Stein DJ, ENIGMA-OCD working group (2022) An overview of the first 5 years of the ENIGMA Obsessive-Compulsive Disorder working group: The power of worldwide collaboration. *Human Brain Mapping*. 43:23-36 (Epub 2020 March 10) doi: 10.1002/hbm.24972
5. Felice F, Schwaller B, Michel T, **Grünblatt E** (2020) Profiling parvalbumin interneurons using iPSC: challenges and perspectives for autism spectrum disorders (ASD). *Mol Autism*. 11(1): 10.
6. Drechsler R, Brem S, Brandeis D, **Grünblatt E**, Berger G, Walitza S (2020) ADHD-Current concepts and treatments in children and adolescents. *Neuropediatrics*. 51(5):315-335. 10.1055/s-0040-1701658.
7. Zai H, Barta C, Cath D, Eapen V, Geller D, **Grünblatt E** (2019) New insights and perspectives on the genetics of obsessive-compulsive disorder. *Psychiatric Genetics*. 29(5): 142-151.
8. Häberling I, Berger G, Schmeck K, Held U, Walitza S and The Omega-3 Study Team (Grünblatt E) (2019) Omega-3 Fatty acids as a treatment for pediatric depression. A phase III, 36 weeks, multi-center, double-blind, placebo-controlled randomized superiority study. *Front. Psychiatry*. 10: 863. 10.3389/fpsyt.2019.00863
9. Andreatza AC, Laksono I, Fernandes BS, Toben C, Lewczuk P, Riederer P, Kenneday S, Kapogiannis D, Thibaut F, Gerlach M, Falo C, Kim YK, **Grünblatt E**, Yatham L, Berk M, Baune BT (2019) Guidelines for the standardized collection of blood-based biomarkers in psychiatry: Steps for laboratory validity- a consensus of the biomarkers task force from the WFSBP. *The World J. Biol. Psych*. 20(5): 340-351. doi: 10.1080/15622975.2019.1574024. (Epub 2019 Mar 25)
10. Fineberg NA, Demetrovics Z, Stein DJ, Ioannidis K, Potenza MN, **Grünblatt E**, Brand M, Billeux J, Carmi L, King D, Grant JE, Yücel M, Dell'Osso B, Rumpf HJ, Hall N, Hollander E, Goudriaan A, Menchon J, Zohar J, Burkauskas K, Martinotti G, Van Ameringen M, Corazza O, Pallanti S, COST Action Network and Chamberlain SR (2018) Manifesto for a European Research Network into Problematic Usage of the Internet. *Eur. Neuropsychopharmacol*. 28(11):1232-1246 (Epub 2018 Oct 2). <https://doi.org/10.1016/j.euroneuro.2018.08.004>
11. Riederer P, Ali S, Bajenaru O., Choi MS., Chopp M., Dobrota V., **Grünblatt E.**, Jellinger K., Kamal MA., Kamal W., Korczyn AD., Leszek J., Michel T., Mushtaq G., Meglic B., Natovich R., Pirtosek Z., Rakusa M., Salkovic-Petrisic M., Schmidt R, Schmitt, A., Sridhar GP., Vecsei L., Wojszel ZB., Yaman H., Zhang ZG., Cukierman-Yaffe T (2017) The diabetic brain and cognition. *J Neural Transm*. 124(11): 1431-1454. (Epub 2017 Aug 1)
12. Sivastav S, Walitza S, **Grünblatt E** (2018) Emerging role of miRNA in Attention deficit hyperactivity disorder: A systematic review. *Atten Defic Hyperact Disord*. 10:49-63. (Epub 2017 May 10) Doi:10.1007/s12402-017-0232-y
13. Schmitt A, Martins-de-Souza D, Akbarian S, Cassoli JS, Ehrenreich H, Fischer A, Fonteh A, Gattaz WF, Gawlik M, Gerlach M, **Grünblatt E**, Halene T, Hasan A, Hashimoto K, Kim YK, Kirchner SK, Kornhuber J, Kraus T, Malchow B, Nascimento JM, Rossner M, Schwarz M, Steiner J, Talib L, Thibaut F, Riederer P, Falkai P and members of the WFSBP Task Force on Biological Markers. (2017) Consensus paper of the WFSBP Task Force on Biological Markers: Criteria for biomarkers and endophenotypes of schizophrenia, part III- Molecular mechanisms. (Epub 2016 Oct 26) *The World J. Biol. Psych*. 18(5): 330-356
14. Bandelow B; Baldwin D; Abelli M; Bolea-Alamanac B; Bourin M; Chamberlain SR; Cinosi E; Davies S; Domschke K; Fineberg N; **Grünblatt E**; Jarema M; Kim YK; Maron E; Masdrakis V; Mikova O; Nutt D; Pallanti S; Pini S; Ströhle A; Thibaut F; Vaghi M; Won E; Wedekind D; Wichniak A; Wooley J; Zwanzger P; Riederer P. (2016) Biological Markers for Anxiety Disorders, OCD and PTSD – A Consensus Statement

- Part II: Neurochemistry, Neurophysiology and Neurocognition. (Epub 2016 Jul 15) *The World J. Biol. Psych.* 18(3): 162-214
15. Bandelow B, Baldwin D, Abelli M, Altamura C, Dell’Osso B, Domschke K, Fineberg N, **Grünblatt E**, Jarema M, Maron E, Nutt D, Pini S, Vaghi MM, Wichniak A, Zai G, Riederer P (2016) Biological markers for Anxiety disorders, OCD and PTSD- A consensus statement- Part I: Neuroimaging and genetics. (Epub 2016 Jul 12) *The World J. Biol. Psych.* 17(5):321-65
  16. **Grünblatt E**, Riederer P (2016) Aldehyde dehydrogenase (ALDH) in Alzheimer’s and Parkinson’s disease. *J Neural Transm.* 123(2): 8390. (Epub 2014 Oct 9).
  17. Marinova Z, Walitza S, **Grünblatt E** (2014) Real-Time Impedance-based cell analyzer as a tool to delineate molecular pathways involved in neurotoxicity and neuroprotection in a neuronal cell line. *JoVE (Journal of Visualized Experiments)*. 90: e51748-e51748. (<http://www.jove.com/video/51748/real-time-impedance-based-cell-analyzer-as-tool-to-delineate>)
  18. **Grünblatt E**, Hauser TU, Walitza S (2014) Imaging genetics in obsessive-compulsive disorder: linking genetic variations to alterations in neuroimaging. *Progress Neurobiol.* 121C: 114-124. DOI: 10.1016/j.pneurobio.2014.07.003 (Epub 2014 Jul 19).
  19. Brem S\*, **Grünblatt E\***, Drechsler R, Riederer P, Walitza S (2014) The neurobiological link between OCD and ADHD. *Atten Defic Hyperact Disord.* 6(3): 175-202. (Epub 2014 Jul 14).(\* both authors contributed equally)
  20. Walitza S, Brem S, Hauser T, **Grünblatt E** (2014) Wie biologisch sind Zwangsstörungen? Genetische Befunde und Bildgebung bei Zwangsstörung. *Kindheit und Entwicklung.* 23(2): 75-85.
  21. Gerlach M, **Grünblatt E**, Lange KW (2013) Is the treatment with psychostimulants in children and adolescents with attention deficit hyperactivity disorder harmful for the dopaminergic system? *J ADHD.* 5(2):71-81. (Epub 2013 Apr 21).
  22. **Grünblatt E**, Bartl J, Marinova Z, Walitza S (2013) In-vitro study methodologies to investigate genetic aspects and effects of drugs used in Attention-deficit Hyperactivity Disorder. *J Neural Transm.* 120(1):131-9. (Epub 2012 July 26)
  23. Fineberg NA, Baldwin DS, Menchon J, Denys D, **Grünblatt E**, Pallanti S, Stein D, Zohar J and the Obsessive Compulsive and Related Disorders Research Network (2012) Manifesto for a European Research Network into Obsessive-Compulsive and Related Disorders. *Eur. Neuropsychopharmacol.* 23(7): 561-8 (Epub. 2012 July 13).
  24. **Grünblatt E** (2012) Parkinson's disease: Molecular risk factors. *Parkinsonism Relat Disord.* 18 Suppl 1: S45-8.
  25. Riederer P, Bartl J, Laux G, **Grünblatt E** (2011) Diabetes Type II: a risk factor for Depression – Parkinson – Alzheimer? *Neurotox. Res.* 19(2): 253-65.
  26. **Grünblatt E**, Bartl J, Riederer P (2011) The link between iron, metabolic syndrome, and Alzheimer’s disease. *J. Neural Transm.* 118(3): 371-379.
  27. Walitza S, Wendland JR, **Grünblatt E**, Warnke A, Sontag TA, Tucha O, Lange KW (2010) Genetics of early-onset obsessive-compulsive disorder. *European Child & Adolescent Psychiatry.* 19(3):227-35.
  28. Salkovic-Petrisic M, Osmanovic J, **Grünblatt E**, Riederer P, Hoyer S (2009) Modeling sporadic Alzheimer disease: The insulin resistant brain state generates multiple long-term morphobiological abnormalities inclusive hyperphosphorylated tau protein and beta-amyloid. A synthesis. *J. Alzheimer Dis.* 18(4): 1387-2877
  29. Stöber G, Ben-Shachar D, Cardon M, Falkai P, Fonteh AN, Gawlik M, Glenthøj BY, **Grünblatt E**, Jablensky A, Kim YK, Kornhuber J, McNeil TF, Müller N, Oranje B, Saito T, Saoud M, Schmitt A, Schwartz M, Thome J, Uzbekov M, Durany N, Riederer P. (2009) Schizophrenia: From the brain to peripheral markers. A consensus paper of the WFSBP task force on biological markers. *World J Biol Psychiatry.* 10(2):127-55.
  30. **Grünblatt E** (2008) Commonalities in the genetics of Alzheimer’s disease and Parkinson’s disease. *Expert Rev. Neurother.* 8(12):1865-77.
  31. Wiltfang J, Lewczuk P, Riederer P, **Grünblatt E**, Hock C, Scheltens P, Hampel H, Vanderstichele H, Iqbal K, Galasko D, Lannfelt L, Otto M, Esselmann H, Henkel AW, Kornhuber J, Blennow K (2005) Consensus paper of the WFSBP Task Force on biological markers of dementia: The role of CSF and blood analysis in the early and differential diagnosis of dementia. *World J. Biol. Psychiatry.* 6 (2): 69-84.
  32. **Grünblatt E.** (2004) The benefits of microarrays as a tool for studying neuropsychiatric disorders. *Drugs of Today.* 40(2): 147-156.

33. Mandel S., **Grünblatt E.**, Riederer P., Gerlach M., Levites Y., Youdim M.B.H. (2003) Neuroprotective Strategies in Parkinson's disease: An Update on Progress. *CNS Drugs*. 17(10): 729-762.
34. Youdim MB, **Grünblatt E.**, Levites Y, Maor G, Mandel S. (2002) Early and late molecular events in neurodegeneration and neuroprotection in Parkinson's disease MPTP model as assessed by cDNA microarray; the role of iron. *Neurotox Res* 4(7-8): 679-689.

#### V. Medical educational journals

1. Re S, Werling AM, Berger G, Walitza S, **Grünblatt E** (2017) Modelling attention-deficit hyperactivity disorder: From hair follicles to neurons using induced pluripotent stem cells. *Leading Opinions Neurologie & Psychiatrie*. 5: 31-33.
2. Walitza S, **Grünblatt E.**, Brem S, Brandeis D, Drechsler R (2015) Was können Biomarker heute leisten? Über den Einsatz von Biomarkern in der psychiatrischen Diagnostik am Beispiel der ADHS. *PSYCH up2date*. 9(2): 65. DOI: 10.1055/s-0041-100216.
3. **Grünblatt E** (2014) Was sind Omics? *PSYCH up2date*. 8(6): 343-346. DOI: 10.1055/s-0034-1387400.

#### VI. Conference manuscripts

1. Riederer P, Youdim MB, Mandel S, Gerlach M, **Grünblatt E.** (2008) Genomic aspects of sporadic Parkinson's disease. *Parkinsonism Relat Disord*. 14 Suppl 2: S88-91.
2. Wultsch T, Chourbaji S, Fritzen S, Kittelt S, **Grünblatt E.**, Gerlach M, Gutknecht L, Chizat F, Golfier G, Schmitt A, Gass P, Lesch LP, Reif A (2007) Behavioural and expressional phenotyping of nitric oxide synthase-I knockdown animals. *J Neural Transm.* (Suppl. 72): 69-85.
3. Kneitz S, Meisner F, Sopper S, Kaiser F, **Grünblatt E.**, Scheller C, Riederer P, ter Meulen V, Koutsilieri E (2007) Biostatistical analysis of gene microarrays reveals diverse expression clusters between macaque subspecies in brain SIV infection. *J Neural Transm.* (Suppl. 72): 317-322.
4. **Grünblatt E.**, Mandel S, Li J, Jacob-Hirsch J, Zeligson S, Amariglio N, Rechavi G, Ravid R, Arzberger T, Roggendorf W, Youdim MBH, Riederer P (2005) Genexpressionanalysen von Substantia-nigra-Gewebe Parkinson-Kranker. *MedReport*. 3 (29. Jahrgang): 4
5. Mandel S, **Grünblatt E.**, Riederer P, Amariglio N, Jacob-Hirsch J, Rechavi G, Youdim MB. (2005) Gene Expression Profiling of Sporadic Parkinson's Disease Substantia Nigra Pars Compacta Reveals Impairment of Ubiquitin-Proteasome Subunits, SKP1A, Aldehyde Dehydrogenase, and Chaperone HSC-70. *Ann N Y Acad Sci*. 1053:356-75.
6. Riederer P., Danielczyk W., **Grünblatt E.** (2004) Monoamine-oxidase-B inhibition in Alzheimer's disease. *Neurotoxicology*. 25 (1-2): 271-277.
7. **Grünblatt E.**, Schlöber R., Gerlach M., Riederer P. (2003) Preclinical versus clinical neuroprotection. *Adv. Neurol.* 91: 309-328.
8. Mandel S, **Grünblatt E.**, Riederer P, Youdim MB. (2003) Genes and oxidative stress in parkinsonism: cDNA microarray studies. *Adv. Neurol.* 91: 123-32.
9. Koutsilieri E., Scheller C., **Grünblatt E.**, Nara K., Li J., Riederer P. (2002) Free radicals in Parkinson's disease. *J. Neurol.* 249(Suppl 2): II/1-II/5.
10. Youdim M.B.H., **Grünblatt E.**, Royak Y. and Mandel S. (2001). Drugs to prevent cell death in Parkinson's disease: Neuroprotection against oxidative stress and inflammatory gene expressions. *Adv. Neurol.* 86: 115-124.
11. **Grünblatt E.**, Mandel S., and Youdim M.B.H. (2000). Neuroprotective strategies in Parkinson's disease using the animal models of 6-hydroxydopamine and MPTP. *Ann. N.Y. Acad. Sci.*, 899: 262-273.
12. **Grünblatt E.**, Mandel S., and Youdim M.B.H. (2000). MPTP and 6-OHDA-induced neurodegeneration as models for Parkinson's disease: neuroprotective strategies. *J. Neurol.*, 247 [Suppl. 2]: II/95-II/102.
13. Youdim M.B.H., Gassen M., Gross A., Mandel S. and **Grünblatt E.** (2000) Iron chelating, antioxidant and cytoprotective properties of dopamine receptor agonist: apomorphine. *J. Neural. Transm. Suppl.* 58: 83-96.
14. Mandel S., **Grünblatt E.** and Youdim M.B.H. (2000) cDNA microarray to study gene expression of dopaminergic neurodegeneration and neuroprotection in MPTP and 6-hydroxydopamine models: implications for idiopathic Parkinson's disease. *J. Neural. Transm. Suppl.* 60: 117-124.
15. **Grünblatt E.**, Mandel S., Gassen, M. and Youdim M.B.H. (1999). Potent neuroprotective and antioxidant activity of apomorphine in MPTP and 6-hydroxydopamine induced neurotoxicity. *J. Neural Transm. (Suppl)* 55: 57-70.

16. Youdim M.B.H., **Grünblatt E.** and Mandel S. (1999) The pivotal role of iron in NF- $\kappa$ B activation and nigro-striatal dopaminergic neurodegeneration; prospects for neuroprotection in Parkinson's Disease with iron chelators. *Ann N.Y. Acad. Sci.* 890:7-25.

## VII. Editorial / Letters

1. King, D. L. & Gaming Industry Response Consortium (Abbott M....**Grünblatt E.**...Walitza S...et al.). (2018). Comment on the global gaming industry's statement on ICD-11 gaming disorder: A corporate strategy to disregard harm and deflect social responsibility? *Addiction*. 113(11): 2145-2146. DOI: [10.1111/add.14388](https://doi.org/10.1111/add.14388).
2. **Grünblatt E.**, Decker J, Gerlach M (2013) *J. Neural Transm.* 120(1):1-2. (Epub 2012 July 13)
3. Mandel S, **Grünblatt E.**, Riederer P (2011) Iron in brain function and neurodegenerative disorders. Editorial. *J. Neural Transm.* 118(3):299-300.

## VIII. Book & Book chapters

1. Yde Ohki, C. M., McNeill, R., Nieberler, M., Radtke, F., Kittel-Schneider, S., **Grünblatt, E.** (2021). Promising developments in use of induced pluripotent stem cells in research of ADHD. In C. Stanford & E. Sciberras (Eds.), *New Discoveries in the Behavioral Neuroscience of Attention Deficit Hyperactivity Disorder*. Springer. (Book chapter). *Curr Topics Behav. Neurosci.* Accepted.
2. **Grünblatt E.** (2021) Genetics of OCD and Related Disorders; Searching for Shared Factors. In "Future Trends In Obsessive-Compulsive And Related Disorders Research" 1<sup>st</sup> Edition, Fineberg N & Robbins TW Editors. (pp. xx). Springer Nature Switzerland AG, *Curr Topics Behav. Neurosci.* 49: 1-16 doi: 10.1007/7854\_2020\_194
3. Finberg N, Dell'Osso B, Demetrovics Z, Chamberline S, Corazza O, Zohar J, Potenza M, Hollander E, Van Ameringen M, Sales C, Jones J, Hall N, Martinotti G, Burkauskas J, Menchon JM, **Grünblatt E.**, Kiraly O (2020) Learning to deal with Problematic Usage of the Internet. COST (European Cooperation in Science and Technology), <https://icocs.org/pui-ebook/>
4. Burton CL, Barta C, Cath D, Geller D, van den Heuvel OA, Yao Y, OCD and TS working group of the PGC, Eapen V\*, **Grünblatt E\***, Zai G\* (2019) Genetics of Obsessive-Compulsive Disorder and Tourette Disorder. In "Personalized Psychiatry", 1<sup>st</sup> Edition, Baune B Editor; (pp. 239-252). San Diego: Academic Press, Elsevier, Published date 1<sup>st</sup> June 2019. ISBN 9780128131763. \*Equal contribution
5. Sian-Hülsmann J, Monoranu CM, **Grünblatt E.**, Riederer P (2018) Neurochemical markers as potential indicators of postmortem tissue quality. In "Handbook of Clinical Neurology", Brain Banking, Huitinga I, Webster MJ Editors; Elsevier; Volume 150, Chapter 9: 119-127. doi: 10.1016/B978-0-444-63639-3.00009-8
6. Koutsilieri E, Arendt G, Neuen-Jacob E, Scheller C, **Grünblatt E.**, Riederer P. (2007) HIV Dementia: A Neurodegenerative Disorder with Viral Etiology. In "Handbook of Neurochemistry and Molecular Neurobiology", 3rd Edition, Degenerative Disease of the Nervous System. Youdim MBH, Riederer P, Mandel SA, Battistin L, Volume Editors; Springer, Berlin, Heidelberg. Chapter 7: 360-371.
7. Weinreb O, Amit T, **Grünblatt E.**, Riederer P, Youdim M., Mandel S. (2007) Gene and Protein Expression Profiling in Parkinson's Disease: Quest for Neuroprotective Drugs. In "Handbook of Neurochemistry and Molecular Neurobiology", 3rd Edition, Degenerative Disease of the Nervous System. Youdim MBH, Riederer P, Mandel SA, Battistin L, Volume Editors; Springer, Berlin, Heidelberg. Chapter 2: 61-78
8. **Grünblatt E.**, Mandel S, Riederer P, Youdim M.B.H (2007) Genes and Oxidative Stress in Sporadic and Familial Parkinsonism: cDNA Microarray Studies. In: Oxidative stress and neurodegenerative disorders. (G.Ali Qureshi & S. Hassan Parvez ed.) Elsevier Press, The Netherlands. Chapter 8: 201-218.
9. Kettler R., Borroni E., Cesura A., **Grünblatt E.**, Jorga K., Richards J.G., Riederer P. and Da Prada M. (2002) Monoamine-oxidase-hemmer: Neurobiochemie, Wirkmechanismus. Pages 474-488 (Riederer P., Laux G. and Pöldinger W., Eds.), *Neuro-Psychopharmaka. Ein Therapie-Handbuch. Band 3: Antidepressiva, Phasenprophylaktika und Stimmungsstabilisierer.* Zweite, neubearbeitete Auflage, Springer-Verlag, Wien, Austria.
10. **Grünblatt E.**, Mandel S., Yona Royak and Youdim, M.B.H. (2001). The contributions of intracellular non-hem iron, NF $\kappa$ B activation and inflammatory responses to neurodegeneration in Parkinson's disease; Prospects for neuroprotection. pp. 277-288. In: Neurotoxic factors in Parkinson's disease and related disorders. (Alexander Storch and, Michael A. Collins, eds.), Springer-Verlag, Wien, Austria.

11. Mandel, S., **Grünblatt, E.**, and Youdim, M. B. H. (2000) cDNA microarray to study gene expression of dopaminergic neurodegeneration and neuroprotection in MPTP and 6-hydroxydopamine models: implications for Parkinson's disease. Pages 117-125 (P. Riederer, D. B. Calne, R. Horowski, Y. Mizuno, C. W. Olanow, W. Poewe, and M. B. H. Youdim, Eds.), *Advances in Neurodegeneration Diseases*, Vol. 8. Springer Medicine, Wien New York.
12. Mandel S., **Grünblatt E.** and Youdim M.B.H. (1999). Therapeutic potential of radical scavengers in Parkinson's disease. *In: Free Radicals in Brain Pathophysiology.* (Poli, G. Cadenas, E., Packer, L., Eds), Marcel Decker press, NY, Chapter. 23, p. 487-500.

### IX. Patent registration

- a. 28<sup>th</sup> July 2005      WO 2005/067391 A2    Diagnostic test for Parkinson's disease (4 Inventors)
- b. 16 June 2009      WO 2009/074331 A3    Early and differential diagnosis test for Alzheimer's disease (2 Inventors)
- c. 3<sup>rd</sup> May 2012      WO 2012/056451 A2    Peripheral blood gene markers for early diagnosis of Parkinson's disease. Inventors. (6 Inventors)

### X. International scientific congresses- Invited speaker or chair (Last 8 years)

- 1) Speaker «Erforschung der Neuroentwicklungsstörung ADHS: Modellierung mit Hilfe personalisierter induzierter pluripotenter Stammzellen» BrainFair 2020, Organized by the Neuroscience centre Zurich, 14-16 March 2022, Zürich, Switzerland.
- 2) Speaker “Wachsen ADHS-Neuronen anders? Eine Untersuchung mit pluripotenten Stammzellen» Schweizerische Fachgesellschaft ADHS, 10 March 2022, Virtual, Switzerland.
- 3) Speaker “Duration of untreated illness and clinical outcomes in childhood and adolescent OCD” ECNP congress, 2-5 October 2021, Lisbon Portugal.
- 4) Chair “Artificial neurons on chip”, ECNP congress, 2-5 October 2021, Lisbon Portugal.
- 5) Speaker “Modelling ADHD: Potentials studying G x E interactions and therapy response”, WASAD congress, 20-22nd Sept 2021, Vienna Austria.
- 6) Speaker “Involvement of the Wnt-signaling pathway in methylphenidate treatment of ADHD” Joint MINDDS-ECNP meeting, Virtual workshop 14-15th Sept 2021
- 7) Speaker “iPSC and ADHD research” Joint McGill-ZNZ Workshop “Induced pluripotent stem cell-based modeling in brain disease research”, 8 December 2020, Virtual (Canada & Switzerland)
- 8) Speaker “Induced pluripotent stem cells to model neurodevelopmental disorders” ESCAP Research academy, Virtual meeting 26<sup>th</sup> August 2020.
- 9) Speaker: «The link between the genetic risk load, anxiety and stress in individuals at clinical high risk for psychosis» 2nd International Congress of the World Assoc. for Stress Related and Anxiety Disorders, 3-5 Oct 2019, Würzburg, Germany.
- 10) Chair: Workshop «Induced pluripotent stem cell models in neuroscience», ZNZ Symposium, 12 Sept 2019, Zürich, Switzerland.
- 11) Speaker: “Was können wir aus personalisierten ADHS-Modellen lernen? Neuronen in der Petrischale» 6. Nationale ADHS Tagung, BeFa 2019, 22 June 2019, Zürich, Switzerland.
- 12) Speakers: “ADHS und Epigenetik” Kinder- und Jugendpsychiatrisches Kolloquium, UPK, University Basel, 22 May 2019, Basel, Switzerland.
- 13) Speaker: Neurobiology seminars Medizinische Wissenschaften ME.5001 “Current knowledge on ADHD and new research approaches”, University of Fribourg, 27 March 2019, Fribourg, Switzerland.
- 14) Speaker: Intern Weiter- und Fortbildung Klinik für Kinder- und Jugendpsychiatrie und Psychotherapie, UZH “Update: ADHS und neue Modelle” 7<sup>th</sup> March 2019, Zurich, Switzerland.
- 15) Speaker: International Training School and Conference on Problematic Usage of the Internet (PUI) “Genetics of behavioural addiction, of relevance to PUI” COST-PUI, 14-16 January 2019, Cambridge, UK.
- 16) Speaker & chair: Brainstorming session “The potentials and limitations of personalized induced pluripotent stem cell (iPSC) models in neuropsychiatry” 31<sup>st</sup> ECNP Congress, 6-9 October 2018, Barcelona, Spain.
- 17) Speaker: “Personalisierte ADHS Modelle” PUK Symposium 2018: ADHS: Überwinden von Defiziten und Störungen, 26 April 2018, Zürich, Switzerland.
- 18) Speaker: “Oxidative stress parameters in a longitudinal aging population- the VITA study” WASAD Congress 2017, 14-17 September 2017, Würzburg, Germany.
- 19) Speaker: “Specificity of Biomarkers for OCD/ADHD” 13<sup>th</sup> World Congress of Biological Psychiatry, 18-22 June 2017, Copenhagen, Denmark.
- 20) Speaker: “The potentials of induced pluripotent stem cells: ADHD model in a dish” 6<sup>th</sup> World Congress on ADHD, 20-23 April 2017, Vancouver, Canada.

- 21) Speaker & chair: Brainstorming session “The current knowledge regarding psychostimulant /methylphenidate effects and mechanism of action in attention-deficit hyperactivity disorder (ADHD) and healthy subjects” 29<sup>th</sup> ECNP Congress, 17-20 September 2016, Vienna, Austria
- 22) Speaker: Epigenetische Veränderungen des serotonergen Systems in Zwangsstörungen im Kindesalter, DGKJP, 25-28 March 2015, München, Germany
- 23) Speaker: Biomarkers in ADHD, 12th World congress of Biological Psychiatry, Symposium: Biomarkers in psychiatric disorders, 14-18 June, Athens, Greece
- 24) Speaker: Epigenetic changes in the serotonergic system in pediatric OCD, 16th ESCAP congress, Symposium: Recent advances in the etiopathogenesis of pediatric OCD and related disorders: epigenetic, autoimmune and environmental aspects, 20-24 June 2015, Madrid, Spain
- 25) Speaker: Methylphenidate treatment in attention-deficit hyperactivity disorder: What do we know about the mechanism of action of methylphenidate? ESCAP congress, 6-10 July 2013, Dublin, Ireland
- 26) Speaker: Mechanism of ADHD treatment with stimulant, World congress on Parkinson's disease and related disorders, 8-11 December 2013, Geneva, Switzerland
- 27) Speaker/ Chair: Genetic Testing: does it make sense?. World congress on Parkinson's disease and related disorders, 8-11 December 2013, Geneva, Switzerland
- 28) Speaker: ADHD medication and its effects on the brain, Hansesymposium, 6-7 Sept 2013, Rostock, Germany
- 29) Speaker/Chair: New findings of copy number variations in Obsessive-Compulsive Disorder, In the symposium: Updates in molecular findings in child and adolescent psychiatry, ECNP congress, 13-17 October 2012, Wien Austria
- 30) Speaker/Chair in the workshop: Research models in ADHD, 3<sup>rd</sup> International congress on ADHD 26-29 May 2011, Berlin, Germany
- 31) Speaker: Biomarker Discovery II, Pathological Biomarkers, WFN-2011 PDRD Satellite Symposium, 15-16 December 2011, Shanghai, China
- 32) Speaker: Parkinson's disease: Molecular risk factors, WFN XIX World Congress on Parkinson's Disease and Related Disorders, 11-14 December 2011, Shanghai, China
- 33) Speaker/Chair: Copy number variations and early onset Obsessive-Compulsive Disorder – implications, World Congress of Biological Psychiatry, 29 May-2 June 2011, Prague